Edmonds Duncan Registered Investment Advisors LLC maintained its position in shares of Johnson & Johnson (NYSE:JNJ) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,250 shares of the company’s stock at the end of the first quarter. Edmonds Duncan Registered Investment Advisors LLC’s holdings in Johnson & Johnson were worth $401,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Nottingham Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 13.4% during the 1st quarter. Nottingham Advisors Inc. now owns 6,791 shares of the company’s stock valued at $846,000 after purchasing an additional 800 shares during the last quarter. NewFocus Financial Group LLC boosted its holdings in shares of Johnson & Johnson by 1.4% during the 1st quarter. NewFocus Financial Group LLC now owns 32,469 shares of the company’s stock valued at $4,044,000 after purchasing an additional 451 shares during the last quarter. Westchester Capital Management Inc. boosted its holdings in shares of Johnson & Johnson by 1.2% during the 1st quarter. Westchester Capital Management Inc. now owns 66,905 shares of the company’s stock valued at $8,333,000 after purchasing an additional 778 shares during the last quarter. Busey Trust CO boosted its holdings in shares of Johnson & Johnson by 0.8% during the 1st quarter. Busey Trust CO now owns 156,656 shares of the company’s stock valued at $19,512,000 after purchasing an additional 1,188 shares during the last quarter. Finally, Xact Kapitalforvaltning AB lifted its holdings in shares of Johnson & Johnson by 7.2% in the 1st quarter. Xact Kapitalforvaltning AB now owns 492,886 shares of the company’s stock valued at $61,389,000 after acquiring an additional 33,153 shares during the last quarter. 66.00% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (NYSE:JNJ) Holdings Maintained by Edmonds Duncan Registered Investment Advisors LLC” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://baseballnewssource.com/markets/edmonds-duncan-registered-investment-advisors-llc-has-401000-position-in-johnson-johnson-jnj/1566570.html.
Johnson & Johnson (JNJ) traded up 0.20% during midday trading on Friday, hitting $134.45. 15,522,011 shares of the stock traded hands. The stock has a market cap of $360.86 billion, a price-to-earnings ratio of 22.75 and a beta of 0.79. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The company has a 50-day moving average price of $132.62 and a 200 day moving average price of $129.18.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.74 EPS. Equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.
In related news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
A number of research analysts recently commented on JNJ shares. Morgan Stanley increased their price target on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. Cowen and Company set a $147.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Thursday, August 24th. UBS AG reaffirmed a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a report on Thursday, August 31st. BidaskClub downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $140.00 price objective on shares of Johnson & Johnson in a research note on Friday, June 16th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $134.60.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.